TY  - JOUR
AU  - Fernandez-Juarez, Gema
AU  - Rojas-Rivera, Jorge
AU  - van de Logt, Anne-Els
AU  - Justino, Joana
AU  - Sevillano, Angel
AU  - Caravaca-Fontan, Fernando
AU  - Avila, Ana
AU  - Rabasco, Cristina
AU  - Cabello, Virginia
AU  - Varela, Alfonso
AU  - Diez, Montserrat
AU  - Martin-Reyes, Guillermo
AU  - Goicoechea Diezhandino, Marian
AU  - Quintana, Luis F.
AU  - Agraz, Irene
AU  - Ramon Gomez-Martino, Juan
AU  - Cao, Mercedes
AU  - Rodriguez-Moreno, Antolina
AU  - Rivas, Begona
AU  - Galeano, Cristina
AU  - Bonet, Jose
AU  - Romera, Ana
AU  - Shabaka, Amir
AU  - Plaisier, Emmanuelle
AU  - Espinosa, Mario
AU  - Egido, Jesus
AU  - Segarra, Alfonso
AU  - Lambeau, Gerard
AU  - Ronco, Pierre
AU  - Wetzels, Jack
AU  - Praga, Manuel
AU  - STARMEN Investigators
PY  - 2021
DO  - 10.1016/j.kint.2020.10.014
SN  - 0085-2538
UR  - https://hdl.handle.net/10668/25928
T2  - Kidney international
AB  - A cyclical corticosteroid-cyclophosphamide regimen is recommended for patients with primary membranous nephropathy at high risk of progression. We hypothesized that sequential therapy with tacrolimus and rituximab is superior to cyclical alternating...
LA  - en
PB  - Elsevier science inc
KW  - corticosteroids
KW  - cyclophosphamide
KW  - primary membranous nephropathy
KW  - rituximab
KW  - tacrolimus
KW  - Nephrotic syndrome
KW  - Phospholipase-a2 receptor
KW  - Plus cyclophosphamide
KW  - Randomized-trial
KW  - Follow-up
KW  - Cyclosporine
KW  - Steroids
KW  - Methylprednisolone
KW  - Chlorambucil
KW  - Remission
TI  - The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy
TY  - research article
VL  - 99
ER  -